Avanir’s Zenvia Set Back Two Years, But Path Forward Is Established With FDA
The company will undertake a new low-dose trial of the involuntary emotional expression disorder treatment to address cardiovascular risks, including QT prolongation.
The company will undertake a new low-dose trial of the involuntary emotional expression disorder treatment to address cardiovascular risks, including QT prolongation.